Covidien PLC VP Coleman N. Lannum III Unloads 13,787 Shares (COV)
Covidien PLC (NYSE:COV) VP Coleman N. Lannum III sold 13,787 shares of the stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $69.23, for a total value of $954,474.01. Following the completion of the sale, the vice president now directly owns 7,564 shares of the company’s stock, valued at approximately $523,656. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Covidien PLC (NYSE:COV) traded up 0.93% during mid-day trading on Thursday, hitting $68.56. 2,186,706 shares of the company’s stock traded hands. Covidien PLC has a 52 week low of $53.0496 and a 52 week high of $70.42. The stock has a 50-day moving average of $67.79 and a 200-day moving average of $64.09. The company has a market cap of $31.017 billion and a price-to-earnings ratio of 18.81.
Covidien PLC (NYSE:COV) last announced its earnings results on Friday, January 24th. The company reported $1.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.06. The company had revenue of $2.64 billion for the quarter, compared to the consensus estimate of $2.61 billion. During the same quarter in the prior year, the company posted $0.97 earnings per share. The company’s quarterly revenue was down 13.6% on a year-over-year basis. On average, analysts predict that Covidien PLC will post $4.00 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Thursday, February 20th. Investors of record on Tuesday, January 28th will be paid a dividend of 0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 1.88%. The ex-dividend date is Friday, January 24th.
COV has been the subject of a number of recent research reports. Analysts at Deutsche Bank raised their price target on shares of Covidien PLC from $75.00 to $77.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at RBC Capital raised their price target on shares of Covidien PLC from $70.00 to $71.00 in a research note to investors on Monday. Finally, analysts at Leerink Swann raised their price target on shares of Covidien PLC from $78.00 to $80.00 in a research note to investors on Monday. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Covidien PLC presently has an average rating of “Buy” and a consensus price target of $74.69.
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.